First Patient Dosed in Ph 1 trial of REC-3565 for R/R B-cell Lymphomas
“REC-3565 showed durable tumor regressions in preclinical studies, both as a monotherapy and in combination with a BTK inhibitor. Leveraging our AI-powered Recursion OS platform, which combines physics-based modeling with molecular dynamics and hotspot analysis, we delivered a lead candidate in just 15 months,” said Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion. “Its allosteric design enhances potency, selectivity, and safety, potentially reducing hyperbilirubinemia risks associated with UGT1A1 inhibition seen in other MALT1 inhibitors. This is particularly promising for patients with B-cell malignancies, where unmet needs remain high.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the